Emcure Pharma Q2 FY27 profit surge and record stock gains
Statements (10 of 15)
- Bullish
Emcure Pharma reported a 29.31% increase in consolidated net profit to ₹325.06 crore during the September quarter
- Bullish
Emcure Pharma stock hit a new high after analysts at Jefferies raised their price target.
- Bullish
Emcure Pharma raised its full-year growth guidance following strong Q2 FY27 results
- Bullish
Emcure Pharmaceuticals reported profit increased 29% and revenue grew 24% in Q2FY27.
- Bullish
Emcure Pharmaceuticals shares rose 16% in two trading sessions, reaching a record high.
- Bullish
Kotak Securities raised its price target for Emcure Pharmaceuticals to ₹2,450.
- Bullish
Emcure Pharmaceuticals posted a consolidated net profit of Rs 325.06 crore for the September quarter.
- Bullish
Emcure Pharma recorded a 34% growth in international business to ₹1,665.2 crore during the quarter
- Bullish
Emcure Pharma's net profit rose 29.31% to ₹325 crore in Q2FY27
- Bullish
Emcure Pharma reported EBITDA of ₹587.3 crore for the quarter, a 23.5% increase from the prior year.
5 more statements on this development this week. The API returns all of them: GET /v2/statements?topic_id=135d8817-c96b-4a0e-8eae-35aded799b95 Get a free API key ↗